CGTX vs. DTIL, ELUT, TIL, JATT, GRTS, CVM, SCYX, ATHA, PLX, and ATRA
Should you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include Precision BioSciences (DTIL), Elutia (ELUT), Instil Bio (TIL), JATT Acquisition (JATT), Gritstone bio (GRTS), CEL-SCI (CVM), SCYNEXIS (SCYX), Athira Pharma (ATHA), Protalix BioTherapeutics (PLX), and Atara Biotherapeutics (ATRA). These companies are all part of the "medical" sector.
Precision BioSciences (NASDAQ:DTIL) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.
38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 5.1% of Precision BioSciences shares are held by company insiders. Comparatively, 20.8% of Cognition Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Cognition Therapeutics has a net margin of 0.00% compared to Cognition Therapeutics' net margin of -48.10%. Precision BioSciences' return on equity of -98.65% beat Cognition Therapeutics' return on equity.
In the previous week, Precision BioSciences had 13 more articles in the media than Cognition Therapeutics. MarketBeat recorded 13 mentions for Precision BioSciences and 0 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.42 beat Precision BioSciences' score of 0.00 indicating that Precision BioSciences is being referred to more favorably in the media.
Cognition Therapeutics has lower revenue, but higher earnings than Precision BioSciences. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.
Precision BioSciences received 80 more outperform votes than Cognition Therapeutics when rated by MarketBeat users. Likewise, 67.18% of users gave Precision BioSciences an outperform vote while only 53.33% of users gave Cognition Therapeutics an outperform vote.
Precision BioSciences currently has a consensus price target of $46.33, suggesting a potential upside of 273.66%. Cognition Therapeutics has a consensus price target of $6.67, suggesting a potential upside of 240.14%. Given Cognition Therapeutics' higher probable upside, equities research analysts plainly believe Precision BioSciences is more favorable than Cognition Therapeutics.
Precision BioSciences has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Cognition Therapeutics has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500.
Summary
Precision BioSciences beats Cognition Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Cognition Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cognition Therapeutics Competitors List
Related Companies and Tools
